EW-7197, a novel ALK-5 kinase inhibitor, potently inhibits breast to lung metastasis

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1704-1716

  Son, Ji Yeon ^a   Park, So Yeon ^a   Kim, Sol Ji ^a   Lee, Seon Joo ^a   Park, Sang A ^a   Kim, Min Jin ^a   Kim, Seung Won ^a   Kim, Dae Kee ^a   Nam, Jeong Seok ^b   Sheen, Yhun Yhong ^a  

^a Ewha Womans University   (South Korea)

^b Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EW 7197; N [[4 ([1,2,4]TRIAZOLO[1,5 A]PYRIDIN 6 YL) 5 (6 METHYLPYRIDIN 2 YL) 1H IMIDAZOL 2 YL]METHYL] 2 FLUOROANILINE; PHOSPHOTRANSFERASE INHIBITOR; SMAD PROTEIN; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; N-((4-((1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-5-(6-METHYLPYRIDIN-2-YL)-1H-IMIDAZOL-2-YL)METHYL)-2-FLUOROANILINE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; TGF-BETA TYPE I RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER CELL CULTURE; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; LIFESPAN; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SURVIVAL TIME; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; HUMAN; LUNG NEOPLASMS; PATHOLOGY; RANDOMIZATION; SECONDARY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RANDOM ALLOCATION; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904169349     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0903     Document Type: Article

References (37)

1. Taylor MA, Parvani JG, Schiemann WP. The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-β in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 2010;15:169-90.
2. Massagué J. How cells read TGF-β signals. Nat Rev Mol Cell Biol 2000;1:169-78.
3. Brown KA, Pietenpol JA, Moses HL. A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-β signaling. J Cell Biochem 2007;101:9-33. (Pubitemid 46652569)
4. Bierie B, Moses HL. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-20. (Pubitemid 43980540)
5. Shi Y, Massagué J. Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell 2003;113:685- 700.
6. Connolly EC, Akhurst RJ. The complexities of TGF-β action during mammary and squamous cell carcinogenesis. Curr Pharm Biotechnol 2011;12:2138.
7. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007;11:259-73. (Pubitemid 46349843)
8. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983-8. (Pubitemid 36418143)
9. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007;58:267-84. (Pubitemid 46706514)
10. McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol Oncol 2010;4:404- 19.
11. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008;100:672-9.
12. Lindley LE, Briegel KJ. Molecular characterization of TGFβ-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells. Biochem Biophys Res Commun 2010;399:659-64.
13. Mani SA, Guo W, Liao M-J, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15. (Pubitemid 351636299)
14. Bhola NE, Balko JM, Dugger TC, Kuba MG, Sánchez V, Sanders M, et al. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 2013;123:1348.
15. Saunier EF, Akhurst RJ. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 2006;6:565-78. (Pubitemid 44691000)
16. Schlingensiepen KH, Fischer-Blass B, Schmaus S, Ludwig S. Antisense therapeutics for tumor treatment: the TGF-beta2 inhibitor AP 12009 in clinical development against malignant tumors. Recent Results Cancer Res 2008:177;137-50.
17. Nam J-S, Terabe M, Mamura M, Kang M-J, Chae H, Stuelten C, et al. An anti-transforming growth factor β antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008;68:3835-43.
18. Yang Ya, Dukhanina O, Tang B, Mamura M, Letterio JJ, MacGregor J, et al. Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002;109:1607-15. (Pubitemid 34663523)
19. Seth P, Wang ZG, Pister A, Zafar MB, Kim S, Guise T, et al. Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-β receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther 2006;17:1152-61.
20. Hu Z, Zhang Z, Guise T, Seth P. Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum Gene Ther 2010;21:1623-9.
21. Bandyopadhyay A, López-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, et al. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res 2002;62:4690-5.
22. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, et al. TGF-β-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011;71:175-84.
23. Tanaka H, Shinto O, Yashiro M, Yamazoe S, Iwauchi T, Muguruma K, et al. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells, and enhances anti-tumor activity. Oncol Rep 2010;24:1637-43.
24. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, Goto K, et al. Ki26894, a novel transforming growth factor-β type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 2007;98:127-33. (Pubitemid 44803931)
25. Zhang M, Kleber S, Röhrich M, Timke C, Han N, Tuettenberg J, et al. Blockade of TGF-β signaling by the TGFßR-I kinase inhibitor LY2109761 enhances radiation response and prolongs survival in glioblastoma. Cancer Res 2011;71:7155-67.
26. Kim DK, Sheen YY, Chenghua J, Park CY, Sreenu D, Sudhakar RK; inventors. 2-Pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors. United States patent US 8080568B1. 2011 Dec 20.
27. Park CY, Son JY, Jin CH, Nam JS, Kim DK, Sheen YY. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Eur J Cancer 2011;47:2642-53.
28. Zhang XHF, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16:67-78.
29. Giampieri S, Pinner S, Sahai E. Intravital imaging illuminates transforming growth factor β signaling switches during metastasis. Cancer Res 2010;70:3435- 9.
30. Akalay I, Janji B, Hasmim M, Noman MZ, André F, De Cremoux P, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013;73:2418-27.
31. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-β type I receptor kinase inhibitor. Cancer Res 2006;66:6714- 21.
32. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, et al. Inhibition of TGF-β 2 with ap 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007;17:201-12. (Pubitemid 47124417)
33. Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, et al. SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65-74. (Pubitemid 34680517)
34. Gadir N, Jackson D, Lee E, Foster D. Defective TGF-β signaling sensitizes human cancer cells to rapamycin. Oncogene 2007;27:1055-62.
35. Filyak Y, Filyak O, Stoika R. Transforming growth factor beta-1 enhances cytotoxic effect of doxorubicin in human lung adenocarcinoma cells of A549 line. Cell Biol Int 2007;31:851-5. (Pubitemid 46765145)
36. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2010;122:409-18.
37. Harper J, Green T, Munroe K, Manning C, Tao J, Simon K, et al. Neutralization of TGFβ enhances the efficacy of chemotherapeutics in a preclinical model of triple negative breast cancer [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl): Abstract nr 3826.